RxDoctor Payments Data

Maria Romero, MD

Ophthalmology · Baltimore, MDNPI 1174722763

Payments from drug & device makers

$9,718in general payments, 2019–2025

Across 142 payments — averaging $68.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$6K
  • Johnson & Johnson Surgical Vision, Inc.$628
  • AbbVie$545
  • Sun Pharmaceutical Industries Inc.$471
  • Glaukos Corporation$460
  • Sight Sciences, Inc.$414
  • plus $2K from 22 others

What the payments were for

  • Consulting fees$5,58257%
  • Food & beverage$4,13643%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,718 in reported general payments places this provider in the 80th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$173,588
Medicare patients
403
Services billed
1,381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TyrvayaVarenicline Tartrate46$30,041
RestasisCyclosporine38$24,274
LumiganBimatoprost23$12,418
Cyclosporine38$8,508
Prednisolone Acetate206$6,965
Travoprost25$5,653
RhopressaNetarsudil Mesylate15$4,698
RocklatanNetarsudil Mesylat/Latanoprost12$3,981
Latanoprost263$3,240
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat104$2,121
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$1,972
Brimonidine Tartrate30$527
Timolol Maleate29$264
ErythromycinErythromycin Base30$257
Ketorolac Tromethamine22$242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$545$36,69261 claims
Oyster Point Pharma, Inc.Tyrvaya$183$30,04146 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$12$8,67927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →